論文・技術情報追加のお知らせ

①The Food and Drug Administration's (FDA's) Drug Safety Surveillance During the COVID-19 Pandemic.

COVID-19パンデミック時のFDA医薬品安全性サーベイランスについて

対象DB：FAERS

②Immune checkpoint inhibitor-induced pure red cell aplasia: Case series and large-scale pharmacovigilance analysis.

免疫チェックポイント阻害剤による純粋赤血球無形成症ファーマコビジランス研究

対象DB：FAERS

③Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the United States Food and Drug Administration Adverse Event Reporting System.

免疫チェックポイント阻害剤誘発性重症筋無力症の特性評価研究

対象DB：FAERS

④A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib.

ニラパリブのファーマコビジランス研究

対象DB：FAERS

⑤Potential safety signal of pregnancy loss with vascular endothelial growth factor inhibitor intraocular injection: A disproportionality analysis using the Food and Drug Administration Adverse Event Reporting System.

血管内皮増殖因子阻害剤眼内注射による妊娠消失のシグナル探索

対象DB：FAERS

⑥Data mining and safety analysis of BTK inhibitors: A pharmacovigilance investigation based on the FAERS database.

BTK阻害剤のデータマイニングと安全性解析調査

対象DB：FAERS

⑦Exploring the underlying mechanisms of drug-induced impulse control disorders: A pharmacovigilance-pharmacodynamic study.

薬物による衝動制御障害メカニズム探索研究

対象DB：FAERS